PTN vs PRGO vs HLN vs DARE vs HIMS

For growth investors, Hims & Hers Health, Inc.

(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -100. 0% for Palatin Technologies, Inc. (PTN). Haleon plc (HLN) offers the better valuation at 19. 0x trailing P/E (22. 2x forward), making it the more compelling value choice. Analysts rate Haleon plc (HLN) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Haleon plc (HLN) is the cheapest at 19.

0x versus Hims & Hers Health, Inc. at 50. 3x. On forward P/E, Perrigo Company plc is actually cheaper at 5. 6x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Hims & Hers Health, Inc.

(HIMS) delivered a total return of +137. 6%, compared to -82. 4% for Daré Bioscience, Inc. (DARE). Over 10 years, the gap is even starker: HIMS returned +161. 9% versus DARE's -99. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Haleon plc (HLN) is the lower-risk stock at 0.

06β versus Hims & Hers Health, Inc. 's 2. 40β — meaning HIMS is approximately 3831% more volatile than HLN relative to the S&P 500. On balance sheet safety, Haleon plc (HLN) carries a lower debt/equity ratio of 52% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Hims & Hers Health, Inc.

(HIMS) is pulling ahead at 59. 0% versus -100. 0% for Palatin Technologies, Inc. (PTN). On earnings-per-share growth, the picture is similar: Daré Bioscience, Inc. grew EPS 88. 4% year-over-year, compared to -1491. 6% for Palatin Technologies, Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Haleon plc (HLN) is the more profitable company, earning 15.

1% net margin versus -414. 3% for Daré Bioscience, Inc. — meaning it keeps 15. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HLN leads at 22. 4% versus -2396. 9% for DARE. At the gross margin level — before operating expenses — PTN leads at 99. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.

6x forward P/E versus 51. 5x for Hims & Hers Health, Inc. — 45. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 70. 6% to $20. 00.

In this comparison, PRGO (9.

8% yield), HLN (1. 9% yield) pay a dividend. PTN, DARE, HIMS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Haleon plc (HLN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

06), 1. 9% yield). Hims & Hers Health, Inc. (HIMS) carries a higher beta of 2. 40 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HLN: +31. 7%, HIMS: +161. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PTN is a small-cap quality compounder stock; PRGO is a small-cap income-oriented stock; HLN is a mid-cap quality compounder stock; DARE is a small-cap quality compounder stock; HIMS is a small-cap high-growth stock. PRGO, HLN pay a dividend while PTN, DARE, HIMS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.